RYLAZE Trademark

Trademark Overview

On Friday, February 7, 2020, a trademark application was filed for RYLAZE with the United States Patent and Trademark Office. The USPTO has given the RYLAZE trademark a serial number of 88789656. The federal status of this trademark filing is REGISTERED as of Tuesday, November 9, 2021. This trademark is owned by Jazz Pharmaceuticals Ireland Limited. The RYLAZE trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of oncological disorders
rylaze

General Information

Serial Number88789656
Word MarkRYLAZE
Filing DateFriday, February 7, 2020
Status700 - REGISTERED
Status DateTuesday, November 9, 2021
Registration Number6555971
Registration DateTuesday, November 9, 2021
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, June 23, 2020

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of oncological disorders

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, February 11, 2020
Primary Code005
First Use Anywhere DateWednesday, June 30, 2021
First Use In Commerce DateWednesday, July 14, 2021

Trademark Owner History

Party NameJazz Pharmaceuticals Ireland Limited
Party Type30 - Original Registrant
Legal Entity Type99 - Other
AddressDublin
IE
Party NameJazz Pharmaceuticals Ireland Limited
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressDublin
IE
Party NameJazz Pharmaceuticals Ireland Limited
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressDublin
IE

Trademark Events

Event DateEvent Description
Tuesday, April 28, 2020NON-FINAL ACTION WRITTEN
Tuesday, February 11, 2020NEW APPLICATION ENTERED
Tuesday, February 11, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, April 27, 2020ASSIGNED TO EXAMINER
Friday, May 8, 2020TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, April 28, 2020NON-FINAL ACTION E-MAILED
Tuesday, April 28, 2020NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, May 14, 2020CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, May 14, 2020TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, May 13, 2020ASSIGNED TO LIE
Tuesday, May 19, 2020APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, June 3, 2020NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, June 23, 2020PUBLISHED FOR OPPOSITION
Tuesday, June 23, 2020OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, August 18, 2020NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Monday, February 15, 2021SOU TEAS EXTENSION RECEIVED
Monday, February 15, 2021SOU EXTENSION 1 FILED
Monday, February 15, 2021SOU EXTENSION 1 GRANTED
Monday, August 16, 2021SOU TEAS EXTENSION RECEIVED
Monday, August 16, 2021SOU EXTENSION 2 GRANTED
Wednesday, February 17, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, August 16, 2021SOU EXTENSION 2 FILED
Wednesday, August 18, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, September 16, 2021TEAS STATEMENT OF USE RECEIVED
Thursday, September 16, 2021USE AMENDMENT FILED
Wednesday, September 29, 2021CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, September 29, 2021STATEMENT OF USE PROCESSING COMPLETE
Tuesday, November 9, 2021REGISTERED-PRINCIPAL REGISTER
Friday, October 1, 2021ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Saturday, October 2, 2021NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Wednesday, October 30, 2024ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY

Related Keywords

rylaze pharmaceutical treatment preparations disorders cancer oncological